{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:25:45Z","timestamp":1758633945843},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s12094-009-0389-8","type":"journal-article","created":{"date-parts":[[2009,7,13]],"date-time":"2009-07-13T20:43:27Z","timestamp":1247517807000},"page":"484-485","source":"Crossref","is-referenced-by-count":4,"title":["Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles"],"prefix":"10.1007","volume":"11","author":[{"given":"Bella","family":"Pajares-Hachero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Hierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,15]]},"reference":[{"key":"389_CR1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.741","volume":"22","author":"J. Meunier","year":"2004","unstructured":"Meunier J, Lumbroso-Le Rouic L, Vincent-Salom\u00f3n A et al (2004) Ophthalmologic and intraocular non-Hodgkin\u2019s lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors. Hematol Oncol 22:143\u2013158","journal-title":"Hematol Oncol"},{"key":"389_CR2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ophtha.2004.07.025","volume":"112","author":"A. Looi","year":"2005","unstructured":"Looi A, Gascoyne RD, Chhanabhai M et al (2005) Mantle cell lymphoma in the ocular adnexal region. Ophthalmology 112:114\u2013119","journal-title":"Ophthalmology"},{"key":"389_CR3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","volume":"10","author":"P. Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 10:750\u2013762","journal-title":"Nat Rev Cancer"},{"key":"389_CR4","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","volume":"39","author":"F. Bertoni","year":"2007","unstructured":"Bertoni F, Ponzoni M (2007) The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 39:1747\u20131753","journal-title":"Int J Biochem Cell Biol"},{"key":"389_CR5","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"J.E. Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA et al (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013\u20137023","journal-title":"J Clin Oncol"},{"key":"389_CR6","first-page":"1418","volume":"17","author":"B.S. Kahl","year":"2006","unstructured":"Kahl BS, Longo WL, Eickhoff JC et al (2006) Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. 17:1418\u20131423","journal-title":"Oncology Network"},{"key":"389_CR7","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R. Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064\u20133071","journal-title":"Blood"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-009-0389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-009-0389-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-009-0389-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:50:46Z","timestamp":1559433046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-009-0389-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s12094-009-0389-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}